thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
In 1210, all Jewish householders in England were imprisoned in Bristol and a hefty levy of 60,000 or 66,000 marks was imposed on them. During the Second Barons' War, the city's archa was burned and the Jewish community was violently attacked. There was another attack in 1275, but without fatalities. The community was expelled with the rest of England's Jews in 1290. There is a surviving Jewish ritual bath, from this time period now known as Jacob's Well. First interpreted as a mikveh, this was subsequently re-evaluated as a Bet Tohorah, associated with the nearby Jewish cemetery at Jews Acre.
Diabetes mellitus is a metabolic disease that is characterized by chronic elevated blood glucose levels (hyperglycemia). Therefore, the main goal of diabetes management is to keep blood glucose levels within normal limits (or a diabetic target range) as often as possible. If diabetes is not well controlled, health challenges may develop. People with diabetes can measure blood glucose by various methods, such as with a glucose meter or a continuous glucose monitor, which monitors over several days. Long-term glucose levels (over 3 months) can also be measured by analysis of a blood sample. In addition to lifestyle modification, some individuals with type 2 diabetes may require medication to adequately control their blood glucose levels. Other goals of diabetes management are prevention or treatment of complications that can result from the disease itself and from its treatment.
The classic click reaction is the copper-catalyzed reaction of an azide with an alkyne to form a 5-membered C2N3 ring. This reaction is the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC). The first triazole synthesis, from diethyl acetylenedicarboxylate and phenyl azide, was reported by Arthur Michael in 1893. Later, in the middle of the twentieth century, this family of 1,3-dipolar cycloadditions took on Rolf Huisgen's name after his studies of their reaction kinetics and conditions.
== Pathophysiology == When small crystalline silica dust particles are inhaled, they can embed themselves deeply into the tiny alveolar sacs and ducts in the lungs, where oxygen and carbon dioxide gases are exchanged. There, the lungs cannot clear out the dust by mucus or coughing. When fine particles of crystalline silica dust are deposited in the lungs, macrophages that ingest the dust particles will set off an inflammatory response by releasing tumor necrosis factors, interleukin-1, leukotriene B4 and other cytokines. In turn, these stimulate fibroblasts to proliferate and produce collagen around the silica particle, thus resulting in fibrosis and the formation of the nodular lesions. The inflammatory effects of crystalline silica are apparently mediated by the NLRP3 inflammasome. Characteristic lung tissue pathology in nodular silicosis consists of fibrotic nodules with concentric "onion-skinned" arrangement of collagen fibers, central hyalinization, and a cellular peripheral zone, with lightly birefringent particles seen under polarized light. The silicotic nodule represents a specific tissue response to crystalline silica. In acute silicosis, microscopic pathology shows a periodic acid-Schiff positive alveolar exudate (alveolar lipoproteinosis) and a cellular infiltrate of the alveolar walls.
The liver synthesizes and stores around 100g of glycogen via glycogenesis, the formation of glycogen from glucose. When needed, the liver releases glucose into the blood by performing glycogenolysis, the breakdown of glycogen into glucose. The liver is also responsible for gluconeogenesis, which is the synthesis of glucose from certain amino acids, lactate, or glycerol. Adipose and liver cells produce glycerol by breakdown of fat, which the liver uses for gluconeogenesis. Liver also does glyconeogenesis which is synthesis of glycogen from lactic acid.
Sources: en.wikipedia.org
=== Later years === Macleod returned to Scotland in 1928 to become Regius Professor of Physiology at the University of Aberdeen (in succession to his former teacher, John Alexander MacWilliam who retired in 1927) and later Dean of the University of Aberdeen Medical Faculty. Between 1929 and 1933 he was also a member of the Medical Research Council. Macleod did not continue to work on insulin, but he remained active as a researcher, lecturer and author. His last major contribution was a proof that the central nervous system does have an important role in maintaining carbohydrate metabolism balance, as was his original hypothesis. His theory about conversion of fats into carbohydrates remained unproven, despite his provision of several indirect proofs. He devoted his spare time to golf, motorcycling and painting. He married Mary Watson McWalter (1876–1940) in 1903, but they never had children. He died in 1935 in Aberdeen after several years of suffering from arthritis, despite which he remained active almost until his death. In 1933 he made a lecture tour of the US, and in 1934 he published the 7th edition of his book Physiology and Biochemistry in Modern Medicine.
== Pathogenesis == The pathogenetic mechanisms of Sjögren's disease have not been fully elucidated, resulting in the lack of pathophysiology knowledge of the management of this autoimmune exocrinopathy. Although the numerous factors contributing to the progression of this disease have made discovering the exact origin and cause difficult, major advances over the past decade have contributed to a proposed set of pathogenic events that occur before the diagnosis of Sjögren's disease. Sjögren's disease was originally proposed as a specific, self-perpetuating, immune system-mediated loss of exocrine glands, specifically acinar and ductal cells. Although this explains the more obvious symptoms (such as the lack of saliva and lacrimal fluid), it does not explain the more widespread systemic effects seen when the disease progresses. In the presence of a susceptible genetic background, both environmental and hormonal factors are thought capable of triggering the infiltration of lymphocytes, specifically CD4+ T cells, B cells, and plasma cells, causing glandular dysfunction in the salivary and lacrimal glands. Sjögren's disease is associated with increased levels in cerebrospinal fluid (CSF) of IL-1RA, an interleukin 1 antagonist. This suggests that the disease begins with increased activity in the interleukin 1 system, followed by an autoregulatory upregulation of IL-1RA to reduce the successful binding of interleukin 1 to its receptors.
== Staining procedural notes == Zenker fixative is preferred, although formalin fixed tissue can be used. If this is the case, the tissue should be mordanted in Zenkers solution before staining. Most texts recommend mordanting in Zenker fixative overnight at room temperature, but it can be done for 3.5 hours in a 56 to 60 degrees Celsius oven. PTAH solution, Gram Iodine, 5% sodium thiosulfate, 0.25% Potassium Permanganate, and 5% Oxalic Acid solution are needed. After staining, slides should be dehydrated quickly because the red-brown components lose their color when exposed to water or alcohol.
12 June – The Green Party launches its manifesto, with key points including increasing taxes for the better off, and higher spending on healthcare, housing and climate change. Sky News presenter Beth Rigby presents an election debate from Grimsby Town Hall, where Sunak and Starmer face questions from an audience. Craig Williams, who served as Sunak's Parliamentary Private Secretary, is being investigated by the Gambling Commission after placing a bet on the date of the general election. Williams subsequently describes the bet as a "huge error of judgement". Dr Anne McCloskey, an independent general election candidate for Foyle, is sentenced to 14 days in prison for non-payment of a COVID-19 related fine by Derry Magistrates. Police say they are aware of YouTuber and internet prankster Niko Omilana, who has registered himself as a general election candidate in 11 different constituencies. 13 June – Keir Starmer unveils the Labour Party's general election manifesto. He says that wealth creation is the "number one priority" and that Labour will focus on economic growth. The Green Party is forced to temporarily remove its manifesto from its website after facing criticism for using an image of an ill man to illustrate its policy on HIV. Plaid Cymru launches its 2024 election manifesto, which includes plans for Welsh independence, 500 extra GPs and funding from rail improvements.
Cardiac alpha actin is a 42.0 kDa protein composed of 377 amino acids. Cardiac alpha actin is a filamentous protein extending from a complex mesh with cardiac alpha-actinin (ACTN2) at Z-lines towards the center of the sarcomere. Polymerization of globular actin (G-actin) leads to a structural filament (F-actin) in the form of a two-stranded helix. Each actin can bind to four others. The atomic structure of monomeric actin was solved by Kabsch et al., and closely thereafter this same group published the structure of the actin filament. Actins are highly conserved proteins; the alpha actins are found in muscle tissues and are a major constituent of the contractile apparatus. Cardiac (ACTC1) and skeletal (ACTA1) alpha actins differ by only four amino acids (Asp4Glu, Glu5Asp, Leu301Met, Ser360Thr; cardiac/skeletal). The actin monomer has two asymmetric domains; the larger inner domain comprised by sub-domains 3 and 4, and the smaller outer domain by sub-domains 1 and 2. Both the amino and carboxy-termini lie in sub-domain 1 of the outer domain.
Sources: en.wikipedia.org
Prior to development of AS9100 standards for Quality Management Systems, the U.S. military applied two specifications to supplier quality and inspection programs, respectively, MIL-Q-9858A Quality Program Requirements, and MIL-I-45208A Military Specification: Inspection System Requirements. For years these specifications had represented the basic tenets of the aerospace industry. However, when the U.S. government adopted ISO 9001, it withdrew those two quality standards. Large aerospace companies then began requiring their suppliers to develop quality programs based on ISO 9001. As technologies evolve, and industries become more specialized, it is likely that more updates will be made to these standards and additional specialty Quality Management Systems (QMS) requirements for various industries.
=== RTG (radioisotope thermoelectric generator) power generation === As 241Am has a roughly similar half-life to 238Pu (432.6 years Am-241, 87.7 years Pu-238, decay energies nearly the same), it has been proposed as an active isotope of radioisotope thermoelectric generators, for use in spacecraft. Even though americium-241 produces less heat and electricity than plutonium-238 (the power yield is 114.7 milliwatts per gram [3.25 watts per ounce] for 241Am vs. 570 mW/g [16 W/oz] for 238Pu) and its radiation poses a greater threat to humans owing to gamma emission, it has advantages for long duration missions with its significantly longer half-life. The European Space Agency is working on RTGs based on americium-241 for its space probes as a result of the global shortage of plutonium-238 and easy access to americium-241 in Europe from nuclear waste reprocessing. Its shielding requirements in an RTG are the second lowest of all possible isotopes: only 238Pu requires less. An advantage over 238Pu is that it is produced as nuclear waste already. Prototype designs of 241Am RTGs expect 2–2.2 We/kg for a 5–50 We design, putting 241Am RTGs at parity with 238Pu RTGs within that power range, as the vast majority of the mass of an RTG is not the radioisotope, but the thermoelectrics, radiators, and isotope containment mass.
1 by the Secretary of State for Home Affairs 1 by the Minister for Transport 6 by the London County Council: 1 by the Corporation of the City of London 1 by the Council of the City of Westminster 6 by the councils of the remaining metropolitan boroughs 2 by the Middlesex County Council 2 by the Essex County Council 1 by the Kent County Council 1 by the Surrey County Council 1 (jointly) by the Buckinghamshire and Hertfordshire County Councils 1 by the Council of the County Borough of Croydon 1 by the Council of the County Borough of East Ham 1 by the Council of the County Borough of West Ham 1 the Secretary of State for Home Affairs to represent the Metropolitan Police 1 the Secretary of State for Home Affairs to represent county and borough police forces in the London Traffic Area 1 by the Corporation of the City of London to represent the City Police 2 by the London Passenger Transport Board 2 by the amalgamated railway companies 5 by the Minister of Labour "after consultation with such bodies representative of those interests as he may think fit to represent the interests of labour engaged in the transport industry within the London Traffic Area" 1 by the Minister for Transport, "after consultation with such bodies representative of those interests as he may think fit, to represent the interests of persons (other than the Board and the amalgamated railway companies) providing or using mechanically-propelled road vehicles within the London Traffic Area" 1 the Minister for Transport, "after consultation with such bodies representative of those interests as he may think fit, to represent the interests of persons (other than the Board and the amalgamated railway companies) providing or using horse-drawn road vehicles within the London Traffic Area" 1 the Minister for Transport, "after consultation with such bodies representative of those interests as he may think fit, to represent the interests of the taxi-cab industry within the London Traffic Area"
They gained promotion to the Championship following a 3–1 win over Millwall in the play-off final later that season. In September 2016, Barnsley were caught up in an ongoing scandal in English football, with assistant manager Tommy Wright alleged to have accepted "bungs" in exchange for working as an ambassador for a third-party player ownership consortium. Wright was suspended and subsequently dismissed by the club.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.